^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    RAF265

    i
    Other names: RAF265, CHIR-265
    Company:
    Novartis
    Drug class:
    BRAF inhibitor, VEGFR-2 inhibitor
    Related drugs:
    over3years
    CHIR-265-MEL01: A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma (clinicaltrials.gov)
    P1/2, N=104, Completed, Novartis Pharmaceuticals | Phase classification: P2 --> P1/2
    Clinical • Phase classification
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    RAF265
    over6years
    MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations (clinicaltrials.gov)
    P1, N=69, Completed, Novartis Pharmaceuticals | Active, not recruiting --> Completed
    Clinical • Trial completion
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600
    |
    Mektovi (binimetinib) • RAF265